CONGENITAL HEART DISEASE TREATMENT

Percutaneous intervention in adults with congenital heart disease has advanced rapidly in recent years and represents a growing field of invasive cardiology. Percutaneous closure of congenital shunts (atrial septal defect (ASD) secundum type, foramen ovale patents, ventricular septal defect (VSD), and patent ductus arteriosus (PDA)) is feasible using modern implantable devices (e.g. Amplatzer occluders).

Valve replacement, stent implantation for native and recurrent coarctation, and ventricular septal defect closure have emerged as attractive alternatives to surgery and have been added to the existing validated procedures (eg, atrial septum defect closure, persistent ductus arteriosus occlusion, and pulmonary valve dilatation).